Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
SMI-4a The evidence points toward a role for LO
2024-11-19

The evidence points toward a role for 12/15-LO activity in WAT in modulating chronic local inflammation and subsequent systemic metabolic decline in the obese state. However, little is known as to the role of 12- and 15-LOs in BAT. Indeed, in addition to WAT, platelet- and leukocyte-type 12-LO are e
-
Regulators of the DDR have therefore become attractive targe
2024-11-19

Regulators of the DDR have therefore become attractive targets for cancer therapy primarily through two potential approaches. First, to be used as chemo- or radiosensitisers to increase the effectiveness of standard genotoxic treatments and to help prevent or overcome the development of resistance.
-
br Materials and methods br
2024-11-19

Materials and methods Results Discussion Because the Ser/Thr kinase domain of LRRK2 is homologous to that of other MLK family proteins belonging to the MAP3K superfamily, LRRK2 is suggested to be involved in MAPK signaling and activation of neuronal cell death by phosphorylating its downstr
-
Knowledge about adipose tissue has
2024-11-19

Knowledge about adipose tissue has evolved considerably over the last two decades. Always been described as an inert tissue having the function of stocking lipids, adipose tissue is now recognized as a real organ with both metabolic and endocrine functions secreting various factors into the blood to
-
Besides Arg overexpression our data revealed that AGEs
2024-11-19

Besides Arg2 overexpression, our data revealed that AGEs could decrease eNOS mRNA levels, which is considered a significant cause for attenuated NO production and vasodilation. It was found recently that AGEs significantly reduce eNOS expression levels and NO bioavailability in human carotid artery
-
br Introduction Sustained over activation of neurohormonal
2024-11-19

Introduction Sustained over-activation of neurohormonal systems is a hallmark in the pathophysiology of cardiac dysfunction following myocardial infarction (MI) and heart failure (HF). Inhibitors of the renin-angiotensin STING pathway activator system (RAAS) constitute cornerstones of pharmacothe
-
Based on the general structure function principle in
2024-11-18

Based on the general structure-function principle in biology [[19], [20], [21]], toxic oligomers are expected to have well-defined three-dimensional structures to carry out their pathological functions. A common amyloid toxicity mechanism also suggests that toxic oligomers of different amyloid prote
-
Dose Response Studies Against Puromycin
2024-11-18

Dose–Response Studies Against Puromycin–Sensitive Aminopeptidase (PSA). PSA is a ubiquitous metallopeptidase encoded by the NPEPPS gene with subcellular distribution in the cytosol and nucleus [49]. Comprising of a 919 amino Ki16198 sequence, it has a broad substrate specificity, and is responsible
-
br Neurological development and BCAAs
2024-11-18

Neurological development and BCAAs Glutamate is an important excitatory neurotransmitter in the brain, and BCAAs (especially leucine) function to synthesize glutamate in astrocytes around neurons, since leucine enters the brain from the blood more rapidly than other gaba receptors and provides ∼
-
br Development of lorlatinib from crizotinib to
2024-11-18

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
Interestingly intermittent high doses of AKT inhibitors
2024-11-18

Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particula
-
Further evidence for action mechanism was provided by assays
2024-11-18

Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t
-
5003 synthesis To verify whether circulating APN
2024-11-18

To verify whether circulating APN could protect cognitive function during aging, we detected the alterations in circulating adipoenctin levels in aging rats. Our results suggested that circulating APN levels reduced with age. Kawasumi et al’s study results are consistent with ours. They concluded th
-
br Concluding Remarks The effects of point mutations
2024-11-18

Concluding Remarks The effects of point mutations of the four ARs on ligand binding affinities, functional potencies, and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allow
-
br Conclusions The present data suggest that homeostatic
2024-11-18

Conclusions The present data suggest that homeostatic balance of the cortical/hippocampal adenosinergic tone is necessary for normal working memory function and any deviation appears to impair performance – either as a consequence of A2AR under-activation when adenosine levels are reduced or due
15885 records 53/1059 page Previous Next First page 上5页 5152535455 下5页 Last page